Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year

CRISPR Therapeutics (NASDAQ: CRSP) has been anything but stable this year. Over the past six months, the stock has experienced sharp swings as the market attempts to determine whether CRISPR is becoming a commercial-stage biotech company or a high-risk clinical-stage play.The answer is somewhere in between.CRISPR Therapeutics' biggest milestone came in late 2023, when CASGEVY, the gene-editing therapy it developed alongside Vertex Pharmaceuticals (NASDAQ: VRTX), became the first CRISPR-based treatment ever approved by regulators for the treatment of sickle cell disease. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool